Barclays Keeps Their Sell Rating on Globus Medical

By Ryan Adsit

In a report issued on November 9, Matthew Taylor from Barclays maintained a Sell rating on Globus Medical (NYSE: GMED), with a price target of $29. The company’s shares closed on Friday at $35.94, close to its 52-week high of $35.96.

According to, Taylor is a 4-star analyst with an average return of 6.5% and a 61.2% success rate. Taylor covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Zimmer Biomet Holdings, and Baxter International.

Globus Medical has an analyst consensus of Moderate Buy, with a price target consensus of $35.08.

The company has a one-year high of $35.96 and a one-year low of $20.52. Currently, Globus Medical has an average volume of 697.1K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Globus Medical, Inc. is a medical device company, which engages in developing products that promote healing in patients with musculoskeletal disorders. It classifies products into Innovative Fusion and Disruptive Technology. It operates through the United States and International geographical segments. The company was founded by David C.